- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Psyence Biomedical invests $2.6m in PsyLabs after milestones met | 3 | Investing.com | ||
| 21.10. | Psyence Biomedical Ltd.: Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met | 1 | GlobeNewswire (USA) | ||
| 21.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 05.10. | Psyence Biomedical Ltd.: Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine | 343 | GlobeNewswire (Europe) | HIGHLIGHTS Texas Ibogaine Research Corporation ("TIRC"), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture... ► Artikel lesen | |
| 05.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 28.09. | Psyence BioMed unit signs term sheet for U.S. ibogaine rights | 2 | Investing.com | ||
| 28.09. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation | 381 | GlobeNewswire (Europe) | NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research... ► Artikel lesen | |
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 23.09. | Psyence BioMed investiert bis zu 5 Mio. USD in PsyLabs und plant Ibogain-Studie | 2 | Investing.com Deutsch | ||
| 23.09. | Psyence Biomedical Ltd.: Psyence BioMed Announces Strategic Ibogaine Investment | 463 | GlobeNewswire (Europe) | Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential... ► Artikel lesen | |
| 23.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.09. | Psyence Biomedical Ltd.: Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development | 332 | GlobeNewswire (Europe) | HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion... ► Artikel lesen | |
| 08.09. | Eli Lilly, AbbVie und Johnson & Johnson: Wie der Fünf-Milliarden-Dollar-Pharma-Run auf Psychedelika Emyria in den Fokus rückt | Small- & Micro Cap Investment | |||
| 18.08. | Psyence BioMed responds to Trump ibogaine announcement | 2 | Investing.com | ||
| 18.08. | Psyence BioMed positioniert sich nach Trump-Ankündigung zu Ibogain | 12 | Investing.com Deutsch | ||
| 18.08. | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development | 319 | GlobeNewswire (Europe) | NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived... ► Artikel lesen | |
| 18.08. | Trump-Ankündigung zu Ibogain lässt Aktie von Psyence Biomedical haussieren | 2 | Investing.com Deutsch | ||
| 06.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 22.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,521 | +2,56 % | Valneva mit PAUKENSCHLAG: Dieses Kursziel lässt Anleger staunen - Jetzt unbedingt lesen! | ||
| BIOFRONTERA | 2,940 | -1,34 % | Biofrontera AG: Was die FDA-Zulassung jetzt verändert | ||
| PALATIN TECHNOLOGIES | 4,550 | -4,61 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,692 | +0,58 % | Note 5- für Ocugen: Warum unsere Experten so hart urteilen - Dringend handeln! | ||
| DEFENCE THERAPEUTICS | 0,225 | -6,25 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,828 | -2,13 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,000 | +1,19 % | H.C. Wainwright bekräftigt Verkaufsempfehlung für Sarepta Therapeutics - Kursziel 5 US-Dollar | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,709 | +22,69 % | Here's Why You Should Hold PacBio Stock in Your Portfolio for Now | ||
| IMMUNITYBIO | 7,820 | +0,90 % | ImmunityBio completes database lock for bladder cancer trial | ||
| REDHILL BIOPHARMA | 0,449 | +0,20 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IMMATICS | 6,675 | +2,30 % | Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting | IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,950 | -4,03 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| TRAWS PHARMA | 0,357 | -0,89 % | Traws Pharma, Inc. - S-1, General form for registration of securities | ||
| VERASTEM | 9,018 | -0,53 % | Novocure und Verastem Oncology kooperieren bei klinischer Studie zu Bauchspeicheldrüsenkrebs | ||
| CURIS | 0,325 | -10,75 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,130 Euro und damit +3,99 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.